Inquiry Basket
Loading ......
Transcription factors serve as primary controllers of gene expression through their ability to impact cellular functions like growth and apoptosis by attaching to DNA sequences and working with co-regulatory proteins. The abnormal behavior of transcription factors contributes to a wide array of diseases including cancer because irregular TF functions promote tumor development and metastasis while creating resistance to treatments. TFs demonstrate therapeutic potential yet remain "undruggable" because researchers find it difficult to target them due to their structural complexity and lack of stable binding pockets. The latest developments in structural biology and drug design together with proteomics research are revealing new methods for targeting previously inaccessible molecules. This review examines the advances made so far in transcription factor-targeted small molecule inhibitors (SMIs) alongside existing obstacles and potential future research directions.
Figure 1. Anatomy of a TF. (Sources: Henley MJ, et al. 2021)
1. Direct Inhibition of DNA-Binding Domains
A primary approach involves disrupting TF-DNA interactions. Napabucasin represents a STAT3 inhibitor that suppresses oncogenic signaling by blocking DNA-binding domains. The BET family inhibitor I-BET762 blocks bromodomains from binding to acetylated histones which leads to the silencing of oncogenes including MYC. These inhibitors target known binding interfaces but still face challenges in achieving specificity.
2. Targeting Protein-Protein Interactions (PPIs)
TFs depend on PPIs for building functionally active complexes. Drugs like MI-773 and RG7388 target the classic cancer protein interaction between p53 and MDM2. These small molecule inhibitors (SMIs) emulate the α-helical structure of p53 to fill MDM2's hydrophobic pocket which leads to p53 stabilization and the reactivation of tumor suppressive functions. NF-κB inhibitors interfere with co-activators such as IKKβ which leads to reduced inflammatory signaling.
3. PROTACs and Molecular Glues
Proteolysis-targeting chimeras (PROTACs) represent a paradigm shift. The bifunctional molecules recruit E3 ubiquitin ligases to mark transcription factors for proteasomal degradation. The compounds HDM201 and ARV-471 which target the estrogen receptor exhibit effectiveness in degrading targets previously considered "undruggable". Molecular glues, such as thalidomide derivatives, induce neo-interfaces between TFs and E3 ligases, offering a compact alternative to PROTACs.
4. Allosteric and Degradation-Independent Modulation
Emerging strategies focus on cryptic or allosteric sites. TEAD inhibitors (e.g., VT3989) bind palmitoylation pockets to disrupt YAP/TAZ-mediated transcription in Hippo pathway-driven cancers. Others stabilize inactive TF conformations, as seen with RUNX inhibitors that impair DNA-binding capacity.
Several TF-targeted SMIs have transitioned to clinical trials, reflecting the field's momentum:
BET Inhibitors: I-BET762 (GSK) and ARV-825 (Arvinas) show promise in hematologic malignancies by silencing MYC and inflammatory genes.
Notch Pathway Inhibitors: CB-103 (Cellestia) blocks Notch signaling, pivotal in T-cell acute lymphoblastic leukemia.
Hippo-TEAD Inhibitors: BPI-460372 (Beta Pharma) targets TEAD palmitoylation, advancing in solid tumors.
IRF5 Inhibitors: HotSpot Therapeutics' lead candidate aims to dampen autoimmune responses by modulating interferon regulatory factors.
Notably, the FDA-approved drug venetoclax, though primarily a BCL-2 inhibitor, underscores the feasibility of targeting PPIs-a principle now being extrapolated to TFs.
1. Structural and Mechanistic Complexity
TFs often lack deep binding pockets and exhibit conformational flexibility. For example, the intrinsically disordered regions of c-MYC or β-catenin complicate rational drug design. Fragment-based screening and cryo-EM are mitigating these issues but require further refinement.
2. Selectivity and Toxicity
Many TFs regulate essential physiological processes. Inhibitors of NF-κB or p53 risk collateral damage to normal cells, necessitating tissue-specific delivery systems or conditional activation strategies.
3. Limitations of PROTACs
While PROTACs expand the druggable proteome, their large size and reliance on E3 ligase expression limit bioavailability and tumor penetration. Additionally, resistance mechanisms, such as ubiquitin protease upregulation, pose long-term challenges.
4. Screening and Validation Hurdles
Traditional high-throughput screens often yield false positives due to TF promiscuity. Advanced models-3D organoids, CRISPR-edited reporter cells, and AI-driven virtual screening-are emerging as solutions.
AI-Driven Drug Discovery: Predictions of TF structures by machine learning models such as AlphaFold allow researchers to perform in silico screening of hidden pockets.
Covalent and Bivalent Inhibitors: KRASG12C inhibitors represent covalent binders that maintain extended target interaction and bivalent molecules function as specific bridges to multiple TF domains.
Epigenetic Combination Therapies: The combination of TF inhibitors with HDAC or DNMT inhibitors can synergistically restore normal transcriptional programming.
Degradation-Repurposing Technologies: AUTACs and LYTACs employ alternative degradation pathways to overcome PROTAC limitations.
SMIs that target transcription factors are transforming precision oncology and autoimmune disease treatment. Despite ongoing challenges interdisciplinary advances like PROTACs and AI research are proving that many proteins previously deemed "undruggable" can be targeted. The expansion of clinical pipelines provides these molecules with great promise to fulfill unmet medical requirements by establishing a novel epoch where genome master regulators serve as pivotal cures.
Transcription factors were deemed "undruggable" due to their flat, dynamic protein-protein interaction (PPI) interfaces, lack of deep binding pockets, and structural heterogeneity. Traditional small molecules struggle to engage these features. However, recent advances have shifted the paradigm:
PROTACs: Bifunctional molecules like ARV-471 degrade TFs by recruiting E3 ligases, bypassing the need for direct inhibition.
Allosteric Modulation: Targeting cryptic pockets (e.g., TEAD palmitoylation sites in the Hippo pathway) or stabilizing inactive conformations (e.g., RUNX inhibitors).
Molecular Glues: Compounds like immunomodulatory drugs (IMiDs) induce neo-interfaces between TFs and ubiquitin ligases.
Fragment-Based Drug Design: Identifying weak binders to shallow TF surfaces and optimizing them into high-affinity inhibitors.
These innovations exploit non-canonical binding mechanisms, transforming TFs from "undruggable" to actionable targets.Key candidates include:
BET Inhibitors: The compounds I-BET762 from GSK and ABBV-744 from AbbVie disrupt MYC-dependent cancers such as AML and prostate cancer by hindering interactions between bromodomains and histones.
Notch Inhibitors: CB-103 (Cellestia) interferes with Notch signaling pathways found in both T-cell leukemia and various solid tumor types.
TEAD Inhibitors: Vivace Therapeutics' VT3989 alongside Beta Pharma's BPI-460372 block YAP/TAZ-TEAD complexes in cancers that show abnormal Hippo pathway activity like mesothelioma.
IRF5 Inhibitors: HotSpot Therapeutics' drug candidates focus on treating autoimmune diseases through interferon response modulation.
p53-MDM2 Antagonists: The drugs AMG 232 (Amgen) and MI-773 (Sanofi) reactivate the p53 tumor-suppressor pathway in cancers with unmutated TP53 genes.
TF inhibitors demonstrate wide-ranging therapeutic applications in both cancer treatment and immune system disorders.
PROTACs and molecular glues circumvent traditional inhibition challenges:
PROTACs: By linking a TF-binding moiety to an E3 ligase recruiter (e.g., VHL or CRBN), they induce TF degradation. Example: DT2216 (Dialectic Therapeutics) targets BCL-XL and is in trials for lymphoma.
Molecular Glues: Compounds like lenalidomide repurpose CRBN ligases to degrade IKZF1/3 in multiple myeloma.
Advantages:
Target degradation eliminates both enzymatic and scaffolding functions of TFs.
Lower doses reduce off-target toxicity.
Address resistance caused by TF overexpression.
Limitations:
Dependency on E3 ligase expression in target tissues.
Large molecular size impacts bioavailability.
These modalities redefine TF druggability, particularly for "undruggable" targets like MYC.
Key hurdles include:
Structural Redundancy: TFs like NF-κB share homologous DNA-binding domains across family members, complicating isoform-specific inhibition.
On-Target Toxicity: TFs like p53 regulate homeostasis; systemic inhibition risks damaging normal cells. Solutions include tissue-specific delivery (e.g., nanoparticle carriers) or conditional activation (e.g., hypoxia-activated prodrugs).
Dynamic PPIs: The transient nature of TF-cofactor interactions (e.g., STAT3 dimerization) demands high-affinity binders.
Screening Limitations: Traditional assays miss allosteric or weak binders. Advances like cryo-EM and AI-predicted binding sites (e.g., AlphaFold) improve hit discovery.
Balancing potency and selectivity remains a cornerstone challenge in TF drug development.
Emerging approaches aim to enhance efficacy and safety:
AI-Driven Discovery: The Atomwise and Schrödinger platforms identify TF-ligand interactions and discover hidden binding sites such as c-MYC inhibitors.
Covalent Inhibitors: Irreversible binders such as KRASG12C inhibitors maintain continuous target engagement for extended times. Example: THZ1 targets CDK7 in MYC-driven cancers.
Dual-Targeting Molecules: Bivalent inhibitors such as STAT3-SH2 domain binders block multiple transcription factor (TF) functions at once.
Epigenetic Combinations: The combination of TF inhibitors with BET or HDAC inhibitors creates a synergistic disruption to oncogenic transcription in cancer cells.
LYTACs/AUTACs: LYTACs and AUTACs function as chimeras that target lysosomes or autophagy mechanisms to degrade transcription factors through alternative degradation pathways which overcome proteasome restrictions.
References
| Target | Cat. No. | Product Name | Type | Host | Conjugate | Application | |
| Cephalosporin | DAG135S | Cephalosporin [BSA] | Synthetic | N/A | BSA | ELISA, LF | Inquiry |
| DAG136S | Cephalosporin [HRP] | Synthetic | N/A | HRP | ELISA, LF | Inquiry | |
| DAG137S | Cephalosporin [KLH] | Synthetic | N/A | KLH | ELISA, LF | Inquiry | |
| Bromobuterol | DAG138S | Bromobuterol [BSA] | Synthetic | N/A | BSA | ELISA, LF | Inquiry |
| DAG139S | Bromobuterol [HRP] | Synthetic | N/A | HRP | ELISA, LF | Inquiry | |
| DAG140S | Bromobuterol [KLH] | Synthetic | N/A | KLH | ELISA, LF | Inquiry | |
| Alternariol | DAG141S | Alternariol [BSA] | Synthetic | N/A | BSA | ELISA, LF | Inquiry |
| DAG142S | Alternariol [HRP] | Synthetic | N/A | HRP | ELISA, LF | Inquiry | |
| DAG143S | Alternariol [KLH] | Synthetic | N/A | KLH | ELISA, LF | Inquiry | |
| Progesterone | DAGA-023PH | Progesterone-3 [HRP] | Synthetic | N/A | HRP | ELISA | Inquiry |
| DAG3019H | Progesterone-11 [HRP] | Synthetic | N/A | HRP | ELISA | Inquiry | |
| Estriol | DAGPYE2301 | 17B(3) ESTRADIOL [HRP] | Synthetic | E.coli | HRP | ELISA, Immunoassays | Inquiry |
| DAGPYE2601 | 17B(6) ESTRADIOL [HRP] | Synthetic | E.coli | HRP | ELISA, Immunoassays | Inquiry | |
| DAG1885 | Estriol(6) [HRP] | Synthetic | N/A | HRP | ELISA | Inquiry | |
| Vitamin B6 | DAG150S | Vitamin B6 [HSA-Biotin] | Synthetic | N/A | HSA-Biotin | ELISA | Inquiry |
| Vitamin B1 | DAG151S | Vitamin B1 [HSA] | Synthetic | N/A | HSA | ELISA | Inquiry |
| Vancomycin | DAG152S | Vancomycin [HSA] | Synthetic | N/A | HSA | ELISA | Inquiry |
| Tyramine | DAG153S | Tyramine [HSA] | Synthetic | N/A | HSA | ELISA | Inquiry |
| Tubocurarine chloride | DAG154S | Tubocurarine chloride [HSA] | Synthetic | N/A | HSA | ELISA | Inquiry |
Loading ......
